Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

New Promise and Opportunities for Allosteric Kinase Inhibitors

Allosterische Kinaseinhibitoren – Erwartungen und Chancen

Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.

Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases

Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Recent Advances in the Development of Allosteric Protein Tyrosine Phosphatase Inhibitors for Drug Discovery.

The Chemical Diversity and Structure-Based Discovery of Allosteric Modulators for the PIF-pocket of Protein Kinase PDK1

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Small Molecule Substrate Phosphorylation Site Inhibitors of Protein Kinases: Approaches and Challenges

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Latent allosteric control of protein interactions by ATP-competitive kinase inhibitors

Insights Into The Impact Of Linker Flexibility And Fragment Ionization On The Design Of Ck2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Protein Allostery in Drug Discovery

Dual Roles of ATP-binding Site in Protein Kinases: Orthosteric Inhibition and Allosteric Regulation.

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives